Effect of interaction between left ventricular dysfunction and endothelial function in hypertension

Angela Sciacqua1, Francesco Borrello, Marco Vatrano

  • 1Department of Medicina Sperimentale e Clinica, Policlinico Mater Domini, Via Tommaso Campanella, 88100 Catanzaro, Italy.

Insights

Hypertension is linked to left ventricular hypertrophy and endothelial dysfunction, increasing cardiovascular risks. Addressing both conditions is crucial for better outcomes in hypertensive patients.

Area of Science:

  • Cardiology
  • Vascular Biology

Background:

  • Hypertension is a major risk factor for cardiovascular diseases.
  • Left ventricular hypertrophy and endothelial dysfunction are independent predictors of clinical events.
  • Endothelial dysfunction impairs antiatherosclerotic and antithrombotic functions, promoting atherosclerosis.
  • Left ventricular hypertrophy independently predicts cardiovascular morbidity and mortality, predisposing to arrhythmias and worsening ischemia outcomes.

Purpose of the Study:

  • To highlight the clinical significance of left ventricular hypertrophy and endothelial dysfunction in hypertension.
  • To emphasize the interaction between endothelial dysfunction and left ventricular mass.
  • To advocate for aggressive therapeutic strategies targeting both conditions in hypertensive patients.

Main Methods:

  • This study is a review of existing literature and clinical observations.
  • Analysis focuses on the independent and combined roles of left ventricular hypertrophy and endothelial dysfunction in hypertensive patients.
  • Clinical implications of the interaction between these two conditions are discussed.

Main Results:

  • Left ventricular hypertrophy and endothelial dysfunction are significant risk factors in hypertension.
  • A dysfunctioning endothelium promotes atherosclerosis.
  • Left ventricular hypertrophy increases the risk of arrhythmias and myocardial ischemia complications.
  • The coexistence of left ventricular hypertrophy and endothelial dysfunction nearly doubles the risk of vascular events in hypertensive individuals.

Conclusions:

  • There is a significant interaction between endothelial dysfunction and left ventricular mass in hypertensive patients.
  • The combined presence of left ventricular hypertrophy and endothelial dysfunction substantially elevates the risk of future vascular events.
  • Aggressive therapeutic strategies aimed at reducing left ventricular mass and improving endothelial function are clinically beneficial for hypertensive patients.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...